Akiyama N, Miyazawa K, Kanda Y, et al. Multicenter phase II trial of vitamin K2 monotherapy and vitamin K2 plus 1[alpha]-hydroxyvitamin D3 combination therapy for low-risk myelodysplastic syndromes. Leukemia Research. 2010;34(9):1151-1157. [Article]
Asakura H, Myou S, Ontachi Y. Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency. Osteoporos Int. 2001;12(12):996-1000. [Article]
co*ckayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ. Vitamin K and the Prevention of Fractures: Systematic Review and Meta-analysis of Randomized Controlled Trials. Arch Intern Med. 2006;166(12):1256-1261. [Article]
Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med. 1994;17(6):531-539. [Article]
Ferland G, Sadowski JA, O’Brien ME. Dietary induced subclinical vitamin K deficiency in normal human subjects. J Clin Invest. 1993;91(4):1761-1768. [Article]
Hodges SJ, Pilkington MJ, Shearer MJ, Bitensky L, Chayen J. Age-related changes in the circulating levels of congeners of vitamin K2, menaquinone-7 and menaquinone-8. Clin Sci (Lond). 1990;78(1):63-66. [Article]
Ide Y, Zhang H, Hamajima H, et al. Inhibition of matrix metalloproteinase expression by menatetrenone, a vitamin K2 analogue. Oncol Rep. 2009;22(3):599-604. [Article]
Iketani T, Kiriike N, Murray, et al. Effect of menatetrenone (vitamin K2) treatment on bone loss in patients with anorexia nervosa. Psychiatry Res. 2003;117(3):259-269. [Article]
Inoue T, Sugiyama T, Matsubara T, Kawai S, Furukawa S. Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol. Endocrine journal. 2001;48(1):11-18. [Article]
Institute of Medicine (U.S.). Panel on Macronutrients., Institute of Medicine (U.S.). Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc. Washington, D.C.: National Academy Press;2001. [Article]
Iwamoto I, Kosha S, Noguchi S-i. A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen-progestin therapy. Maturitas. 1999;31(2):161-164. [Article]
Iwamoto J, Matsumoto H, Takeda T, Sato Y, Yeh J. Effects of Vitamin K2 on Cortical and Cancellous Bone Mass, Cortical Osteocyte and Lacunar System, and Porosity in Sciatic Neurectomized Rats. Calcif Tissue Int. 2010;87(3):254-262. [Article]
Iwamoto J, Seki A, Sato Y, Matsumoto H, Tadeda T, Yeh J. Vitamin K2 Promotes Bone Healing in a Rat Femoral Osteotomy Model with or without Glucocorticoid Treatment. Calcif Tissue Int. 2010;86(3):234-241. [Article]
Iwasaki Y, Yamato H, Murayama H, et al. Menatetrenone prevents osteoblast dysfunction in unilateral sciatic neurectomized rats. Japanese journal of pharmacology. 2002;90(1):88-93. [Article]
Jiang Y, Zhang Z-L, Zhang Z-L, et al. Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial. Clinical Interventions in Aging. 2014;9:121-127. [Article]
McKeown NM, Jacques PF, Gundberg CM, et al. Dietary and nondietary determinants of vitamin K biochemical measures in men and women. J Nutr. 2002;132(6):1329-1334. [Article]
Miyazawa K, Nishimaki J, Ohyashiki K, et al. Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan. Leukemia. 2000;14(6):1156-1157. [Article]
Nishiguchi S, Shimoi S, Kurooka H. Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. Journal of Hepatology. 2001;35(4):543-545. [Article]
Onodera K, Takahashi A, Sakurada S, Okano Y. Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sciences. 2002;70(13):1533-1542. [Article]
Purwosunu Y, Muharram, Rachman IA, Reksoprodjo S, Sekizawa A. Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia. J Obstet Gynaecol Res. 2006;32(2):230-234. [Article]
Sasaki N, Kusano E, Takahashi H, et al. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). Journal of bone and mineral metabolism. 2005;23(1):41-47. [Article]
Sasaki N, Kusano E, Takahashi H, et al. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). Journal of bone and mineral metabolism. 2005;23(1):41-47. [Article]
Sato Y, Honda Y, Kuno H, Oizumi K. Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone. 1998;23(3):291-296. [Article]
Schurgers LJ, Teunissen KJF, Hamulyak K, Knapen MHJ, Vik H, Vermeer C. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. 2007;109(8):3279-3283. [Article]
Shikano K, Kaneko K, Kawazoe M, Kaburaki M, Hasunuma T, Kawai S. Efficacy of Vitamin K2 for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases. Internal Medicine. 2016;55(15):1997-2003. [Article]
Shiomi S, Nishiguchi S, Kubo S. Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. The American Journal of Gastroenterology. 2002;97(4):978-981. [Article]
Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (Menatetrenone) Effectively Prevents Fractures and Sustains Lumbar Bone Mineral Density in Osteoporosis. Journal of Bone and Mineral Research. 2000;15(3):515-522. [Article]
Somekawa Y, Chigughi M, Harada M, Ishibashi T. Use of vitamin K2 (menatetrenone) and 1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide. J Clin Endocrinol Metab. 1999;84(8):2700-2704. [Article]
Sugiyama T, Tanaka H, Kawai S. Clinical vignette. Vitamin K plus vitamin D treatment of bone problems in a child with skeletal unloading. J Bone Miner Res. 1999;14(8):1466-1467. [Article]
Takami A, Asakura H, Nakao S. Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome. Ann Hematol. 2002;81(1):16-19. [Article]
Ushiroyama T, Ikeda A, Ueki M. Effect of continuous combined therapy with vitamin K2 and vitamin D3 on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas. 2002;41(3):211-221. [Article]
Yasui T, Miyatani Y, Tomita J. Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women. Gynecological Endocrinology. 2006;22(8):455-459. [Article]
Yonemura K, f*ckasawa H, Fujigaki Y, Hishida A. Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine. Am J Kidney Dis. 2004;43(1):53-60. [Article]
Yonemura K, f*ckasawa H, Fujigaki Y, Hishida A. Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine. Am J Kidney Dis. 2004;43(1):53-60. [Article]
Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis. Calcified tissue international. 2000;66(2):123-128. [Article]
